ଆଭାକୋପାନ

ଆଭାକୋପାନ
Clinical data
Trade names	Tavneos, Vynpenta
Synonyms	CCX168
AHFS/Drugs.com	monograph
data	US DailyMed: Avacopan;
Routes of; administration	By mouth
Legal status
Legal status	CA: ℞-only ; US: ℞-only ; EU: Rx-only ; Rx-only;
Identifiers
ECHA InfoCard	100.351.344
Chemical and physical data
Formula	C33H35F4N3O2
Molar mass	୫୮୧.୬୬ g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC1=CC=C(NC(=O)[C@H]2CCCN([C@H]2C2=CC=C(NC3CCCC3)C=C2)C(=O)C2=C(F)C=CC=C2C)C=C1C(F)(F)F;
	InChI InChI=1S/C33H35F4N3O2/c1-20-12-15-25(19-27(20)33(35,36)37)39-31(41)26-10-6-18-40(32(42)29-21(2)7-5-11-28(29)34)30(26)22-13-16-24(17-14-22)38-23-8-3-4-9-23/h5,7,11-17,19,23,26,30,38H,3-4,6,8-10,18H2,1-2H3,(H,39,41)/t26-,30-/m0/s1; Key:PUKBOVABABRILL-YZNIXAGQSA-N;

ଆଭାକୋପାନ (ଇଂରାଜୀ ଭାଷାରେ Avacopan), ଟାଭ୍ନୋସ୍ ଏକ ବିକ୍ରୟ ନାମ, ହେଉଛି ଏକ ଔଷଧ ଯାହା ଆଣ୍ଟି-ନିଉଟ୍ରୋଫିଲ ସାଇଟୋପ୍ଲାଜାମିକ ଅଟୋଆଣ୍ଟିବଡି (ANCA)-ଆସୋସିଏଟେଡ୍ ଭାସ୍କୁଲାଇଟିସ ରୋଗର ଚିକିତ୍ସା ପାଇଁ ବ୍ୟବହୃତ ହୁଏ । ^[୩] ଏଥିରେ ଗ୍ରାନୁଲୋମାଟୋସିସ ସ‌ହିତ ପଲିଆଞ୍ଜାଇଟିସ (GPA) ଏବଂ ଅଣୁବୀକ୍ଷଣୀୟ ପଲିଆଞ୍ଜାଇଟିସ (MPA) ଥାଏ ।^[୨] ଏହା ପାଟିରେ ଦିଆଯାଏ ।^[୩]

ସାଧାରଣ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ଅଇ, ମୁଣ୍ଡବିନ୍ଧା, ସ୍ୱଳ୍ପ ଶ୍ୱେତ ରକ୍ତ କଣିକା, ଉର୍ଦ୍ଧ୍ୱ ଶ୍ୱାସନଳୀ ସଂକ୍ରମଣ, ତରଳ ଝାଡ଼ା, ବାନ୍ତି ଏବଂ ନାକ ତ‌ଥା ଗଳାର ପ୍ରଦାହ ହୋଇପାରେ ।^[୨] ଅନ୍ୟ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ଯକୃତ ସମସ୍ୟା, ଆଲର୍ଜି ପ୍ରତିକ୍ରିୟା ଏବଂ ସଂକ୍ରମଣ ଅନ୍ତର୍ଭୁକ୍ତ ହୋଇପାରେ ।^[୩] ଗର୍ଭାବସ୍ଥାରେ ସୁରକ୍ଷା ଅସ୍ପଷ୍ଟ ଅଟେ ।^[୩] ଏହା ଏକ କପ୍ଲିମେଣ୍ଟ ୫ଏ ରିସେପ୍ଟର (C5aR) ବିରୋଧୀ ଅଟେ ।^[୩]

୨୦୨୧ ମସିହାରେ ଜାପାନ ଓ ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଏବଂ ୨୦୨୨ରେ ୟୁରୋପରେ ଡାକ୍ତରୀ କ୍ଷେତ୍ରରେ ବ୍ୟବହାର ପାଇଁ ଆଭାକୋପାନ ଅନୁମୋଦିତ ହୋଇଥିଲା ।^[୪] ^[୩] ^[୨] ଯୁକ୍ତରାଜ୍ୟରେ ୨୦୨୨ ସୁଦ୍ଧା ଏକ ମାସର ଔଷଧ ଖର୍ଚ୍ଚ ପ୍ରାୟ ୫୫୦୦ ପାଉଣ୍ଡ ଥିଲା ।^[୫] ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଏହି ରାଶିର ମୂଲ୍ୟ ପ୍ରାୟ ୧୪,୪୦୦ ଡଲାର ଅଟେ ।^[୬]

ଆଧାର

↑ "Summary Basis of Decision - Tavneos". Health Canada. 28 July 2022. Archived from the original on 29 September 2022. Retrieved 29 September 2022.
↑ ^୨.୦ ^୨.୧ ^୨.୨ ^୨.୩ "Tavneos EPAR". European Medicines Agency. 10 November 2021. Archived from the original on 17 March 2022. Retrieved 24 April 2022. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
↑ ^୩.୦ ^୩.୧ ^୩.୨ ^୩.୩ ^୩.୪ ^୩.୫ ^୩.୬ "Tavneos- avacopan capsule". DailyMed. Archived from the original on 1 November 2021. Retrieved 31 October 2021.
↑ ^୪.୦ ^୪.୧ "ChemoCentryx Announces Approval in Japan of Tavneos (Avacopan) for the Treatment of ANCA-Associated Vasculitis". ChemoCentryx, Inc. (Press release). 27 September 2021. Archived from the original on 9 October 2021. Retrieved 11 October 2021.
↑ "Avacopan". SPS - Specialist Pharmacy Service. 23 October 2017. Archived from the original on 6 December 2021. Retrieved 25 October 2022.
↑ "Avacopan". Goodrx. Archived from the original on 25 October 2022. Retrieved 25 October 2022.

[1] "Summary Basis of Decision - Tavneos". Health Canada. 28 July 2022. Archived from the original on 29 September 2022. Retrieved 29 September 2022.

[EPAR2022-2] ୨.୦ ^୨.୧ ^୨.୨ ^୨.୩ "Tavneos EPAR". European Medicines Agency. 10 November 2021. Archived from the original on 17 March 2022. Retrieved 24 April 2022. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.

[PI2022-3] ୩.୦ ^୩.୧ ^୩.୨ ^୩.୩ ^୩.୪ ^୩.୫ ^୩.୬ "Tavneos- avacopan capsule". DailyMed. Archived from the original on 1 November 2021. Retrieved 31 October 2021.

[Chem2021-4] ୪.୦ ^୪.୧ "ChemoCentryx Announces Approval in Japan of Tavneos (Avacopan) for the Treatment of ANCA-Associated Vasculitis". ChemoCentryx, Inc. (Press release). 27 September 2021. Archived from the original on 9 October 2021. Retrieved 11 October 2021.

[5] "Avacopan". SPS - Specialist Pharmacy Service. 23 October 2017. Archived from the original on 6 December 2021. Retrieved 25 October 2022.

[6] "Avacopan". Goodrx. Archived from the original on 25 October 2022. Retrieved 25 October 2022.

[୩]

[୨]

[୧]

[୪]

[୫]

[୬]